Research and Development

Marketed & Developmental Products (U.S.)

The following table summarizes the status of products marketed, approved and/or under advanced development by Noven. Developmental products are identified in yellow.

Product	Indication	Regulatory Status	Marketing Rights
Noven Therapeutics Central Nervous System
Daytrana^®(methylphenidate transdermal system)	ADHD in children 6-17 years old	Marketed in U.S.	Noven
Stavzor^® (valproic acid delayed release capsules)	Bipolar disorder, migraine & epilepsy	Marketed in U.S.	Noven
Pexeva^® (paroxetine mesylate)	Depression, panic disorder, OCD & GAD	Marketed in U.S.	Noven
Lithobid^® (lithium carbonate)	Bipolar disorder	Marketed in U.S.	Noven
Noven Therapeutics Women's Health
Minivelle^® (estradiol transdermal system)	Moderate to severe vasomotor symptoms	Marketed in U.S.	Noven
Vivelle-Dot^® (estradiol transdermal system)	Moderate to severe vasomotor symptoms; moderate to severe vulvar and vaginal atrophy; treatment of hypoestrogenism; osteoporosis	Marketed in U.S.	Novogyne¹
CombiPatch^® (estradiol / NETA transdermal system)	Moderate to severe vasomotor symptoms; moderate to severe vulvar and vaginal atrophy; treatment of hypoestrogenism	Marketed in U.S.	Novogyne (co-promoted by Noven)
LDMP (low-dose mesylate salt of paroxetine)	Non-hormonal therapy for moderate to severe vasomotor symptoms	NDA under FDA review	Noven
Pain Management
Fentanyl Transdermal System (generic)	Persistent, moderate to severe chronic pain	Marketed in U.S.	Upsher-Smith Laboratories, Inc.
Lidocaine Topical Patch (generic)	Pain related to post herpetic neuralgia	ANDA under FDA review	Noven
Other Areas
Rivastigmine Transdermal System	Mild to moderate dementia of the Alzheimer's type	ANDA under FDA review	Noven
Parent Company Collaboration
Multiple Undisclosed Projects	Various	Pre-clinical and clinical development	Hisamitsu/Noven

¹	Novogyne Pharmaceuticals is a joint venture between Noven and Novartis Pharmaceuticals Corporation.